Showing results (1601-1610 of 1,729) with videos related to
Sort By:
Pageof 173
Technology in Cancer Research & Treatment|September 7, 2010
A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancerEric K Oermann, Rebecca S Slack, Heather N Hanscom, et al.Annals of Surgical Oncology|November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 StudyRüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialPhilipp Harter, Frederik Marmé, Andrés Redondo, et al.The New England Journal of Medicine|December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerIsabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.Geburtshilfe Und Frauenheilkunde|October 29, 2019
Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.Geburtshilfe Und Frauenheilkunde|December 5, 2022
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA studyPaul Sabbatini, Philipp Harter, Giovanni Scambia, et al.BMC Cancer|February 11, 2025
The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitorsGwenn Le Gall, François Cherifi, Jordane Divoux, et al.Nature|September 9, 2021
The EDS1-PAD4-ADR1 node mediates Arabidopsis pattern-triggered immunityRory N Pruitt, Federica Locci, Friederike Wanke, et al.Pageof 173